A Sign of the Times: Chi-Med’s MediPharma Steps Toward Independence
This article was originally published in PharmAsia News
Executive Summary
Accompanying the solid interim results announced by Hutchison China MediTech this week was an interesting indication of both the success of Chi-Med's Hutchison MediPharma R&D subsidiary and the evolution of the nascent biotech industry in China
You may also be interested in...
China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen
BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives
China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen
BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives
Chi-Med CEO Christian Hogg: An Interview With PharmAsia News (Part 2 of 2)
Chi-Med CEO Christian Hogg sat down recently with PharmAsia News to discuss how traditional Chinese medicine (TCM) serves as both the foundation for Chi-Med's success and as its platform for growth. Chi-Med is focused on researching, developing, manufacturing and selling pharmaceuticals, health supplements and other health care and personal care products derived from TCM and botanical ingredients.